Skip to search form
Skip to main content
Skip to account menu
Semantic Scholar
Semantic Scholar's Logo
Search 225,385,852 papers from all fields of science
Search
Sign In
Create Free Account
Diquafosol
Known as:
diuridine 5'-(pentahydrogen tetraphosphate) tetrasodium salt
National Institutes of Health
Create Alert
Alert
Related topics
Related topics
4 relations
Diquafosol Tetrasodium
Narrower (1)
INS-365
Broader (2)
Polyphosphates
Uracil Nucleotides
Papers overview
Semantic Scholar uses AI to extract papers important to this topic.
2017
2017
Immediate Effect of 3% Diquafosol Ophthalmic Solution on Tear MUC5AC Concentration and Corneal Wetting Ability in Normal and Experimental Keratoconjunctivitis Sicca Rat Models
Kwang-Eon Choi
,
J. Song
,
Boram Kang
,
Y. Eom
,
Hyo-Myung Kim
Current Eye Research
2017
Corpus ID: 13918576
ABSTRACT Purpose: To evaluate the immediate effect of 3% diquafosol ophthalmic solution on tear MUC5AC concentration, periodic…
Expand
2017
2017
Changes in Tear Volume after 3% Diquafosol Treatment in Patients with Dry Eye Syndrome: An Anterior Segment Spectral-domain Optical Coherence Tomography Study
Kwan Bok Lee
,
K. Koh
,
Young A Kwon
,
S. Song
,
B. Kim
,
J. Chung
Korean Journal of Ophthalmology
2017
Corpus ID: 2062056
Purpose To evaluate changes in the tear meniscus area and tear meniscus height over time in patients with dry eye syndrome, using…
Expand
2016
2016
Influence of Ophthalmic Solutions on Tear Components
C. Shigeyasu
,
M. Yamada
,
Yoko Akune
Cornea
2016
Corpus ID: 26077033
Abstract: Tear fluids are a mixture of secretions derived from lacrimal glands, accessory lacrimal glands, conjunctiva, and…
Expand
2016
2016
The Effect of 3% Diquafosol Tetrasodium on Corneal Wetting Property and Mucin-5AC Concentration in Rabbits
D. Yeon
,
Boram Kang
,
Y. Eom
,
Hyo Myung Kim
,
J. Song
2016
Corpus ID: 76029478
Purpose: To evaluate the immediate effects of 3% diquafosol ophthalmic solution on tear MUC5AC concentration and corneal wetting…
Expand
2015
2015
Diquafosol sodium ophthalmic solution for the treatment of dry eye: clinical evaluation and biochemical analysis of tear composition
C. Shigeyasu
,
M. Yamada
,
Yoko Akune
,
K. Tsubota
Japanese Journal of Ophthalmology
2015
Corpus ID: 8559366
PurposeTo evaluate the clinical efficacy of 3 % diquafosol sodium ophthalmic solution for dry eye, and to analyze the…
Expand
2014
2014
The effects of 3% diquafosol sodium application on the tear functions and ocular surface of the Cu,Zn-superoxide dismutase-1 (Sod1)–knockout mice
Takashi Kojima
,
M. Doğru
,
+8 authors
K. Tsubota
Molecular Vision
2014
Corpus ID: 6175934
Purpose To investigate the role of a water and mucin secretagogue (3% diquafosol sodium eye drops) on the tear function and…
Expand
2014
2014
Clinical Usefulness of Diquafosol for Real-World Dry Eye Patients: A Prospective, Open-Label, Non-Interventional, Observational Study
Masahiko YamaguchiTakeshi
2014
Corpus ID: 75457595
Introduction: This study was designed to evaluate the efficacy and safety of 3% diquafosol ophthalmic solution in dry eye…
Expand
2014
2014
Das Trockene Auge
A. Schachner
Der Ophthalmologe
2014
Corpus ID: 20638942
Zwischen 10 und 20% der erwachsenen Bevolkerung Mitteleuropas leiden laut Experten an Keratokonjunktivitis sicca, dem trockenen…
Expand
2007
2007
New approaches in Sjögren’s syndrome therapy
M. Ramos-Casals
,
P. Brito‐Zerón
Expert Review of Clinical Immunology
2007
Corpus ID: 19910541
At present, there is no treatment capable of modifying the evolution of Sjögren’s syndrome (SS) and the therapeutic approach is…
Expand
Review
2005
Review
2005
Recent advances in the management of ocular complications of sjögren’s syndrome
M. Samarkos
,
H. Moutsopoulos
Current Allergy and Asthma Reports
2005
Corpus ID: 36450274
Sjögren’s syndrome (SS) is an autoimmune disorder, the principal ocular manifestation of which is decreased tear production…
Expand
By clicking accept or continuing to use the site, you agree to the terms outlined in our
Privacy Policy
(opens in a new tab)
,
Terms of Service
(opens in a new tab)
, and
Dataset License
(opens in a new tab)
ACCEPT & CONTINUE